MedTrace Logo

A Study of K-645 in the Treatment of Multiple Migraine Attacks

NCT07116499 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2025-11-25

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine.

Conditions

  • Acute Migraine

Interventions

DRUG

Placebo

Single oral dose of matching placebo

DRUG

K-645 dose level 1

Single oral dose of K-645 dose level 1

DRUG

K-645 dose level 2

Single oral dose of K-645 dose level 2

Sponsors & Collaborators

  • Kallyope Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-12
Primary Completion
2025-11-07
Completion
2025-11-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07116499 on ClinicalTrials.gov